-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Contrast agent, also known as contrast agent, is a subsidiary industry of medical imaging equipment
.
When the differential diagnosis of some diseases is difficult through conventional imaging examinations, the contrast agent is injected into the human body to enhance the contrast of the images, so that tumors and some cardiovascular diseases can be differentially diagnosed
.
Contrast agents can be mainly divided into X-ray contrast agents, magnetic resonance contrast agents and ultrasound contrast agents
.
Due to the popularization of X-ray and CT angiography, non-ionic organic iodine contrast agents represented by iohexol and iodixanol (which have the advantages of low osmotic pressure, good tolerance, and stable performance) have been widely used, occupying the majority of contrast agents.
Half of the market
.
It is worth noting that compared with most pharmaceutical sub-sectors, there are fewer original manufacturers and imitation manufacturers in the contrast agent industry, and most product patents have expired for many years, but there is still only one original researcher, or 1-3 imitations.
Therefore, In recent years, more and more domestic enterprises have begun to pay attention to this market prospect, and they have also launched their layout in the field of non-ionic organic iodine contrast agents, and have made a lot of new progress
.
For example, recently, Hengrui Medicine and Beilu Pharmaceutical Co.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Data show that gadobutrol injection is a gadolinium-based non-ionic contrast agent, which is mainly used for magnetic resonance imaging examination of systemic lesions and whole-body magnetic resonance angiography examination
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
The data shows that in 2021, Bayer's sales revenue of Galexian will be 418 million euros.
In 2020, the sales of terminal gadobutrol in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 50 million yuan
.
Hengrui Medicine submitted a generic application for the product in November 2012, but did not complete the review and approval until April 2020
.
At present, in addition to Hengrui and Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Kelun Pharmaceuticals, etc.
have also submitted applications for the product's listing one after another
.
The industry expects that the market competition in this field will continue to intensify in the future
.
It should be noted that, with the rapid development of the contrast agent industry, its market size has become larger and larger, but its market structure has also been basically formed
.
Today, almost every product market has been firmly controlled by giants in this field, such as Hengrui, Yangzijiang, Bracco, GE, Bayer, and Beilu Pharmaceuticals, all of which have been deeply involved in the contrast agent market for many years
.
Therefore, other domestic pharmaceutical companies still have a long way to go if they want to compete for this market
.
If you do not have the determination and strength to enter the contrast agent market, it is not recommended for those who do not have relevant market resources to easily intervene
.
For companies with contrast agent approval documents, the industry believes that in order to gain more competitiveness, they need to further expand their contrast agent product lines, or they can choose to combine powerful forces to jointly respond to policy changes and market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
When the differential diagnosis of some diseases is difficult through conventional imaging examinations, the contrast agent is injected into the human body to enhance the contrast of the images, so that tumors and some cardiovascular diseases can be differentially diagnosed
.
Contrast agents can be mainly divided into X-ray contrast agents, magnetic resonance contrast agents and ultrasound contrast agents
.
Due to the popularization of X-ray and CT angiography, non-ionic organic iodine contrast agents represented by iohexol and iodixanol (which have the advantages of low osmotic pressure, good tolerance, and stable performance) have been widely used, occupying the majority of contrast agents.
Half of the market
.
It is worth noting that compared with most pharmaceutical sub-sectors, there are fewer original manufacturers and imitation manufacturers in the contrast agent industry, and most product patents have expired for many years, but there is still only one original researcher, or 1-3 imitations.
Therefore, In recent years, more and more domestic enterprises have begun to pay attention to this market prospect, and they have also launched their layout in the field of non-ionic organic iodine contrast agents, and have made a lot of new progress
.
For example, recently, Hengrui Medicine and Beilu Pharmaceutical Co.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Data show that gadobutrol injection is a gadolinium-based non-ionic contrast agent, which is mainly used for magnetic resonance imaging examination of systemic lesions and whole-body magnetic resonance angiography examination
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
The data shows that in 2021, Bayer's sales revenue of Galexian will be 418 million euros.
In 2020, the sales of terminal gadobutrol in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 50 million yuan
.
Hengrui Medicine submitted a generic application for the product in November 2012, but did not complete the review and approval until April 2020
.
At present, in addition to Hengrui and Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Kelun Pharmaceuticals, etc.
have also submitted applications for the product's listing one after another
.
The industry expects that the market competition in this field will continue to intensify in the future
.
It should be noted that, with the rapid development of the contrast agent industry, its market size has become larger and larger, but its market structure has also been basically formed
.
Today, almost every product market has been firmly controlled by giants in this field, such as Hengrui, Yangzijiang, Bracco, GE, Bayer, and Beilu Pharmaceuticals, all of which have been deeply involved in the contrast agent market for many years
.
Therefore, other domestic pharmaceutical companies still have a long way to go if they want to compete for this market
.
If you do not have the determination and strength to enter the contrast agent market, it is not recommended for those who do not have relevant market resources to easily intervene
.
For companies with contrast agent approval documents, the industry believes that in order to gain more competitiveness, they need to further expand their contrast agent product lines, or they can choose to combine powerful forces to jointly respond to policy changes and market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
